Publications by authors named "T Hagihara"
Gastric cancer (GC) is a major cause of global cancer mortality with high levels of heterogeneity. To explore geospatial interactions in tumor ecosystems, we integrated 2,138 spatial transcriptomic regions-of-interest (ROIs) with 152,423 single-cell expression profiles across 226 GC samples from 121 patients. We observed pervasive expression-based intratumor heterogeneity, recapitulating tumor progression through spatially localized and functionally ordered subgroups associated with specific immune microenvironments, checkpoint profiles, and genetic drivers such as SOX9.
View Article and Find Full Text PDFIntroduction: Pressurized intraperitoneal aerosol chemotherapy-oxaliplatin (PIPAC-OX) induces direct DNA damage and immunogenic cell death in patients with gastric cancer peritoneal metastases (GCPM). Combining PIPAC-OX with immune checkpoint inhibition remains untested. We conducted a phase I first-in-human trial evaluating the safety and efficacy of PIPAC-OX combined with systemic nivolumab (NCT03172416).
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the genetic and environmental factors that lead to peritoneal metastasis (PM) in gastric cancer (GC), which typically has a poor prognosis.
- Researchers conducted a detailed analysis of samples from 326 patients, looking at various genetic and expression changes in tumors and their surroundings.
- Findings revealed specific genetic mutations and tumor microenvironment characteristics that enhance the risk of PM, along with potential therapeutic targets to improve treatment strategies for patients with GC.
Article Synopsis
- * This study created a specific 18-nucleotide ASO (SY-ODN18) that effectively activates TLR9, demonstrating that an unmethylated CpG motif at the beginning is crucial for this activation.
- * The research also found that using sugar-modified nucleotides in ASO designs decreases TLR9 stimulation, which is a key consideration for developing effective ASO-based drugs.
Background: Conversion surgery (CS) after chemotherapy is weakly recommended as a promising tool for improving prognoses in patients with unresectable gastric cancer. Moreover, several investigators have demonstrated the clinical efficacy of subtotal gastrectomy (sTG) with a small remnant stomach for the nutritional status and surgical outcome compared with total gastrectomy. Here, we report a patient with liver metastasis from human epidermal growth factor receptor 2 (HER2)-positive gastric cancer who underwent sTG and hepatectomy after trastuzumab-based chemotherapy.
View Article and Find Full Text PDF